IQVIA Q3 Revenue Rises 8% to $4.43 Billion; Raises 2026 Guidance
IQVIA reported Q3 2026 revenue of $4.43B, up 8% YoY, and adjusted EPS of $3.34, up 11.3%. Net income was $350M, with adjusted EBITDA at $1.03B. The company raised its 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS. Commercial and R&D solutions saw revenue growth, with R&D bookings up 15% YoY.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance suggest stronger demand for its services, likely boosting investor sentiment.
Market read
First‑report earnings and guidance lift for a large‑cap health‑tech firm, high trading relevance.
What to watch
Potential headwinds from regulatory changes or slower payer adoption could temper growth.
Background
IQVIA is a leading provider of data, analytics, and technology solutions to the life‑sciences industry.
Ticker impact
IQVIA reported Q3 2026 revenue up 8% to $4.43B and raised full-year 2026 guidance.
upward pressure as investors price in higher revenue and earnings expectations
The earnings beat and guidance lift are fresh primary disclosures for a large‑cap health‑data company.
Market effects
Health‑data and contract research services sector may see broader optimism.
U.S. market participants may bid up related biotech and pharma service stocks.
Limited to investors tracking U.S. health‑tech earnings.
Counterpoint
If guidance raise is already priced in, the stock could face a short‑term pullback.
Key entities
- companyIQVIA Holdings Inc.
Provider of health‑care data and analytics.
